Etoposide hypersensitivity reactions and outcomes of desensitizations in immediate-type hypersensitivity reactions

Gözde Köycü Buhari; Sakine Nazik Bahçecioğlu; Selcan Gültuna; Özgür Akkale; Hatice Çelik Tuğlu; Onur Telli; Fatma Dindar Çelik; Melis Yağdıran; Dilek Çuhadar; Şenay Demir; Kurtuluş Aksu

Makale detayları

Etoposide hypersensitivity reactions and outcomes of desensitizations in immediate-type hypersensitivity reactions

Yazarlar:

Gözde Köycü Buhari | Sakine Nazik Bahçecioğlu | Selcan Gültuna | Özgür Akkale | Hatice Çelik Tuğlu | Onur Telli | Fatma Dindar Çelik | Melis Yağdıran | Dilek Çuhadar | Şenay Demir | Kurtuluş Aksu

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Alerji | Solunum Hastalıkları

Dergi:

Anatolian Current Medical Journal Vol.6 Issue 2, pp.175-180

Belge Tipi:

Makale

Yayın Tarihi:

8/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001312925

pISSN:

2718-0115

Anahtar kelimeler:

Özet:

 Aims: This study aims to define characteristics of hypersensitivity reactions with etoposide, and outcomes of desensitizations in immediate-type hypersensitivity rections Methods: This is a retrospective observational study of patients who had hypersensitivity reactions with etoposide from January 2019 to December 2023. Results: A total of 39 patients with lung cancer were included in the study. Ten 25.6 patients had known other drug allergies and three 7.7 patients had previous chemotherapeutic hypersensitivity two with paclitaxel and one with docetaxel. Most of the initial hypersensitivities were in the first or second cycle n29, 74.4. Ten 25.4 patients had hypersensitivity reactions at the first application of etoposide. Thirty 76.9 patients had immediate-type hypersensitivity reactions. There was no significant difference in terms of patient and initial hypersensitivity characteristics between patients who had immediate or non-immediate type hypersensitivity reactions. Of the 30 patients with immediate-type hypersensitivity reactions, initial reaction was mild in 16 53.3 and moderate in 14 46.7 patients. Most common symptoms were erythema in 29 96.7, dyspnea in 13 43.3, chest tightness in 8 26.7, discomfortness in 7 23.3, and hypertension in 6 20. Skin tests were negative in five patients who underwent skin testing. A total of 98 desensitization courses were performed in 27 patients and 3 11.1 patients had breakthrough reactions. Conclusion: Most of the hypersensitivity reactions to etoposide are immediate-type and not severe. Desensitization is an effective and safe procedure to manage these reactions. Further research is needed to elucidate the mechanisms of hypersensitivity reactions.

 Aims: This study aims to define characteristics of hypersensitivity reactions with etoposide, and outcomes of desensitizations in immediate-type hypersensitivity rections Methods: This is a retrospective observational study of patients who had hypersensitivity reactions with etoposide from January 2019 to December 2023. Results: A total of 39 patients with lung cancer were included in the study. Ten 25.6 patients had known other drug allergies and three 7.7 patients had previous chemotherapeutic hypersensitivity two with paclitaxel and one with docetaxel. Most of the initial hypersensitivities were in the first or second cycle n29, 74.4. Ten 25.4 patients had hypersensitivity reactions at the first application of etoposide. Thirty 76.9 patients had immediate-type hypersensitivity reactions. There was no significant difference in terms of patient and initial hypersensitivity characteristics between patients who had immediate or non-immediate type hypersensitivity reactions. Of the 30 patients with immediate-type hypersensitivity reactions, initial reaction was mild in 16 53.3 and moderate in 14 46.7 patients. Most common symptoms were erythema in 29 96.7, dyspnea in 13 43.3, chest tightness in 8 26.7, discomfortness in 7 23.3, and hypertension in 6 20. Skin tests were negative in five patients who underwent skin testing. A total of 98 desensitization courses were performed in 27 patients and 3 11.1 patients had breakthrough reactions. Conclusion: Most of the hypersensitivity reactions to etoposide are immediate-type and not severe. Desensitization is an effective and safe procedure to manage these reactions. Further research is needed to elucidate the mechanisms of hypersensitivity reactions.

 Aims: This study aims to define characteristics of hypersensitivity reactions with etoposide, and outcomes of desensitizations in immediate-type hypersensitivity rections Methods: This is a retrospective observational study of patients who had hypersensitivity reactions with etoposide from January 2019 to December 2023. Results: A total of 39 patients with lung cancer were included in the study. Ten 25.6 patients had known other drug allergies and three 7.7 patients had previous chemotherapeutic hypersensitivity two with paclitaxel and one with docetaxel. Most of the initial hypersensitivities were in the first or second cycle n29, 74.4. Ten 25.4 patients had hypersensitivity reactions at the first application of etoposide. Thirty 76.9 patients had immediate-type hypersensitivity reactions. There was no significant difference in terms of patient and initial hypersensitivity characteristics between patients who had immediate or non-immediate type hypersensitivity reactions. Of the 30 patients with immediate-type hypersensitivity reactions, initial reaction was mild in 16 53.3 and moderate in 14 46.7 patients. Most common symptoms were erythema in 29 96.7, dyspnea in 13 43.3, chest tightness in 8 26.7, discomfortness in 7 23.3, and hypertension in 6 20. Skin tests were negative in five patients who underwent skin testing. A total of 98 desensitization courses were performed in 27 patients and 3 11.1 patients had breakthrough reactions. Conclusion: Most of the hypersensitivity reactions to etoposide are immediate-type and not severe. Desensitization is an effective and safe procedure to manage these reactions. Further research is needed to elucidate the mechanisms of hypersensitivity reactions.

 Aims: This study aims to define characteristics of hypersensitivity reactions with etoposide, and outcomes of desensitizations in immediate-type hypersensitivity rections Methods: This is a retrospective observational study of patients who had hypersensitivity reactions with etoposide from January 2019 to December 2023. Results: A total of 39 patients with lung cancer were included in the study. Ten 25.6 patients had known other drug allergies and three 7.7 patients had previous chemotherapeutic hypersensitivity two with paclitaxel and one with docetaxel. Most of the initial hypersensitivities were in the first or second cycle n29, 74.4. Ten 25.4 patients had hypersensitivity reactions at the first application of etoposide. Thirty 76.9 patients had immediate-type hypersensitivity reactions. There was no significant difference in terms of patient and initial hypersensitivity characteristics between patients who had immediate or non-immediate type hypersensitivity reactions. Of the 30 patients with immediate-type hypersensitivity reactions, initial reaction was mild in 16 53.3 and moderate in 14 46.7 patients. Most common symptoms were erythema in 29 96.7, dyspnea in 13 43.3, chest tightness in 8 26.7, discomfortness in 7 23.3, and hypertension in 6 20. Skin tests were negative in five patients who underwent skin testing. A total of 98 desensitization courses were performed in 27 patients and 3 11.1 patients had breakthrough reactions. Conclusion: Most of the hypersensitivity reactions to etoposide are immediate-type and not severe. Desensitization is an effective and safe procedure to manage these reactions. Further research is needed to elucidate the mechanisms of hypersensitivity reactions.

Makale detayları

Etoposide hypersensitivity reactions and outcomes of desensitizations in immediate-type hypersensitivity reactions

Yazarlar:

Gözde Köycü Buhari | Sakine Nazik Bahçecioğlu | Selcan Gültuna | Özgür Akkale | Hatice Çelik Tuğlu | Onur Telli | Fatma Dindar Çelik | Melis Yağdıran | Dilek Çuhadar | Şenay Demir | Kurtuluş Aksu

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Alerji | Solunum Hastalıkları

Dergi:

Anatolian Current Medical Journal Vol.6 Issue 2, pp.175-180

Belge Tipi:

Makale

Yayın Tarihi:

8/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001312925

pISSN:

2718-0115

Etoposide

hypersensitivity

desensitization

reaction

immediate

chemotherapy

Sayı

Makale detayları

Etoposide hypersensitivity reactions and outcomes of desensitizations in immediate-type hypersensitivity reactions

Yazarlar: Gözde Köycü Buhari | Sakine Nazik Bahçecioğlu | Selcan Gültuna | Özgür Akkale | Hatice Çelik Tuğlu | Onur Telli | Fatma Dindar Çelik | Melis Yağdıran | Dilek Çuhadar | Şenay Demir | Kurtuluş Aksu

Yayıncı: MediHealth Academy Yayıncılık

Ana Başlıklar: Alerji | Solunum Hastalıkları

Dergi: Anatolian Current Medical Journal Vol.6 Issue 2, pp.175-180

Belge Tipi: Makale

Yayın Tarihi: 8/2024

Belge Dili: İngilizce

Document ID (Org No.): 2001312925

pISSN: 2718-0115

Etoposide

hypersensitivity

desensitization

reaction

immediate

chemotherapy

Sayı

Yazarlar:

Gözde Köycü Buhari | Sakine Nazik Bahçecioğlu | Selcan Gültuna | Özgür Akkale | Hatice Çelik Tuğlu | Onur Telli | Fatma Dindar Çelik | Melis Yağdıran | Dilek Çuhadar | Şenay Demir | Kurtuluş Aksu

Yayıncı:

MediHealth Academy Yayıncılık

Ana Başlıklar:

Alerji | Solunum Hastalıkları

Dergi:

Anatolian Current Medical Journal Vol.6 Issue 2, pp.175-180

Belge Tipi:

Makale

Yayın Tarihi:

8/2024

Belge Dili:

İngilizce

Document ID (Org No.):

2001312925

pISSN:

2718-0115